Related Experiment Videos
[Betaxolol treatment of hypertension in postmenopausal women]
Aim:
The study of hypotensive efficacy of high-cardioselective beta-blocker betaxolol, its effects on lipid and carbohydrate metabolism, menopausal syndrome in females with mild and moderate arterial hypertension.
Materials And Methods:
20 postmenopausal 45-59-year-old women entered the trial of betaxolol. They had diastolic blood pressure 90-114 mm Hg. Beta-blockers were not contraindicated. Arterial pressure, heart rate, body mass, blood lipid spectrum, glucose and insulin levels were evaluated before the treatment, 1, 3 and 6 months after it.
Results:
Betaxolol safely and effectively lowered blood pressure. Blood lipid spectrum remained unchanged. A transitory rise in fasting insulin levels did not worsen glucose tolerance despite a small gain in body mass. Menopausal syndrome relieved due to good effect of betaxolol on vasomotor disorders.
Conclusion:
Betaxolol has a good hypotensive effect in the absence of adverse effects on lipid and carbohydrate metabolism. A reduction of menopausal syndrome was also achieved.
Insights
High-cardioselective beta-blocker betaxolol effectively lowers blood pressure in women with hypertension. It also improves menopausal symptoms without negatively impacting lipid or carbohydrate metabolism.
Area of Science:
- Cardiology
- Endocrinology
- Women's Health
Background:
- Arterial hypertension is a prevalent condition in postmenopausal women.
- Managing hypertension requires careful consideration of metabolic and menopausal side effects.
Purpose of the Study:
- To evaluate the hypotensive efficacy of the high-cardioselective beta-blocker betaxolol.
- To assess betaxolol's effects on lipid and carbohydrate metabolism.
- To determine the impact of betaxolol on menopausal syndrome in hypertensive women.
Main Methods:
- A trial involving 20 postmenopausal women (45-59 years) with mild to moderate hypertension.
- Evaluation of arterial pressure, heart rate, body mass, lipid profile, glucose, and insulin levels.
- Measurements taken before and at 1, 3, and 6 months after betaxolol treatment.
Main Results:
- Betaxolol demonstrated safe and effective blood pressure reduction.
- No significant changes were observed in the blood lipid spectrum.
- A transient increase in fasting insulin levels did not impair glucose tolerance, despite minor weight gain.
- Significant relief of menopausal symptoms, particularly vasomotor disorders, was noted.
Conclusions:
- Betaxolol offers a beneficial hypotensive effect for hypertensive postmenopausal women.
- The drug exhibits a favorable metabolic profile, with no adverse effects on lipid or carbohydrate metabolism.
- Betaxolol effectively alleviates menopausal syndrome, improving overall quality of life.